The outcome of stable disease is consistent with preclinical studies showing that DS‐1205c restored the antitumor activity of erlotinib in an erlotinib acquired‐resistance EGFR‐mutant NSCLC tumor xenograft mouse model.12 This evidence concerns the gene EGFR and non-small cell lung carcinoma.